Inhibitors of human immunodeficiency virus replication

Abstract

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:

What is claimed is: 
     
         1 . A compound of Formula II: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         G 1  is phenyl substituted once with —N(CH 3 )S(O 2 )CH 3 , —S(O 2 )C(CH 3 ) 3 , —CHF 2 , —CF 3 , —OCHF 2 , —OCF 3 , or —C(CH 3 ) 2 OH, or G 1  is one of the following: 
       
       
         
           
           
               
               
           
         
         G 2  and G 3  are independently selected from is H or —CH 3 ; 
         G 4  is H, —CH 3 , or —OCH 3 ; 
         G 4 a is —CH 3 , or —OCH 3 ; 
         G 5  is —CH 3 , or CH 2 CH 3 ; 
         G 6  is H, —CH 3 , or CH 2 CH 3 ; 
         G 7  is ethyl, isopropyl, tert-butyl, —CHF 2 , or —CF 3 ; 
         G 8  is H, methyl, ethyl, —CHF 2 , —CF 3 , —OCH 3 , or —OCH 2 CH 3 ; 
         G 9  is ethyl, isopropyl, cyclopropyl, —CH 2 OH, —OCH 3 ; 
         G 10  is ethyl, isopropyl, cyclopropyl, tert-butyl, —CHF 2 , or —CF 3 ; 
         G 11  is methyl, —OCH 3 , —CHF 2 , —CF 3 , —S(O 2 )CH 3 ; 
         G 12  is F, —CH 3 , —CHF 2 , —CF 3 , —OCH 3 , —S(O 2 )CH 3 ; 
         G 13  is C 1 -C 4 alkyl, C 1 -C 6 cycloalkyl, —CH 2 O(C 1 -C 3  alkyl); 
         G 14  is H, C 1 -C 4 alkyl, —CHF 2 , —CF 3 , —O(C 1 -C 3  alkyl); 
         G 15  is H, F, —CH 3 , or OCH 3 ; 
         R 3  is H, F, Cl, —CH 3 , or —OCH 3 ; 
         R 4  is H or C 1 -C 3 alkyl wherein C 1 -C 3  alkyl is optionally substituted with 1-3 fluorines; 
         R 5  is C 1 -C 6  alkyl or C 3 -C 6  cycloalkyl; 
         W is selected from: 
       
       
         
           
           
               
               
           
         
         where R 6  is methyl optionally substituted with 1 to 3 fluorines. 
       
     
     
         2 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 1  wherein W is 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 1  wherein R 3  is Cl; R 4  is —CH 3 , —CH 2 CHF 2 , or —CH 2 CF 3 ; and R 5  is methyl or cyclopropyl. 
     
     
         4 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 3  wherein R 3  is Cl; R 4  is —CH 3 , and R 5  is methyl. 
     
     
         5 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 1  wherein G 1  is one of the following: 
       
         
           
           
               
               
           
         
       
     
     
         6 . A compound or a pharmaceutically acceptable salt thereof, according  claim 1  wherein G 1  is one of the following: 
       
         
           
           
               
               
           
         
       
     
     
         7 . A compound or a pharmaceutically acceptable salt thereof, according to  claim 1  wherein G 1  contains a fluorine atom. 
     
     
         8 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof, according to  claim 1  further comprising a pharmaceutically acceptable carrier, excipient, and/or diluent. 
     
     
         9 . (canceled) 
     
     
         10 . A method of treating HIV infection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound according to  claim 1 . 
     
     
         11 . The method of  claim 10  wherein said administration is oral. 
     
     
         12 . The method of  claim 10  wherein said administration is by subcutaneous injection. 
     
     
         13 . The method of  claim 10  wherein said administration is by intramuscular injection. 
     
     
         14 . The method of  claim 10  wherein said method further comprises administration of at least one other agent useful in the prevention or treatment of HIV. 
     
     
         15 . The method of  claim 14  wherein said other agent is selected from the group consisting of dolutegravir, lamivudine, fostemsavir, and cabotegravir.